Cochrane Review Group

Haematology

78 systematic reviews in Haematology ask 987 questions. 25.9% have no studies to answer them, 21% rest on very low certainty evidence and 21.6% reach moderate or high certainty.

Reviews

Questions

987

current versions

No studies

25.9%

Moderate or high

21.6%

No studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Haematology

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Intervention NR All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane	RR 1 [0.27, 3.7]	3 studies · 451 participants	Very low
Intervention NR Number of participants with any bleeding ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Number of participants with clinically significant bleeding · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane	no estimate extracted	1 study · 84 participants	Very low
Intervention NR Serious infections ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Length of hospital admission ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Hospital readmission rate ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Quality of life (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane	no estimate extracted	3 studies · 431 participants	Very low
Intervention NR All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane	no estimate extracted	1 study · 84 participants	Very low
Intervention NR Quality of life ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane	no estimate extracted	NR	No studies
Immunomodulatory drug maintenance therapy vs placebo/observation Treatment discontinuation · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane	Risk ratio 0.71 [0.47, 1.05]	2 studies · 400 participants	Very low
Anti‐CD52 mAb maintenance therapy vs observation Overall survival – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane	no estimate extracted	NR	No studies
Anti‐CD52 mAb maintenance therapy vs observation Health‐related quality of life – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane	no estimate extracted	NR	No studies

Reviews 78

Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition

Fisher, SA, Cutler, A, et al. · Cochrane Database of Systematic Reviews · 2019

Haematology

Thinnest evidence

Reviews 78

Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition

Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use undergoing non‐cardiac surgery or invasive procedures

Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: a network meta‐analysis

Effects of all‐trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (non‐APL))

Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)

Prophylactic platelet transfusions prior to surgery for people with a low platelet count

Bisphosphonates in multiple myeloma: an updated network meta‐analysis

Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma

Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma

Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression‐free survival: individual participant data analysis

Pathogen‐reduced platelets for the prevention of bleeding

Thrombopoietin mimetics for patients with myelodysplastic syndromes

Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in patients with solid tumours

Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes

The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving erythropoiesis‐stimulating agents

Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders

Bortezomib for the treatment of multiple myeloma

Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation

Meditation for adults with haematological malignancies

Plasma transfusions prior to insertion of central lines for people with abnormal coagulation

Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta‐analysis and systematic review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy

Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell transplantation